AIM Vaccine Co., Ltd.

6660

CNE100005KF2

Pharmaceuticals

Market Closed - Hong Kong S.E. Other stock markets 09:08:17 17/05/2024 BST			5-day change	1st Jan Change
8.03 ^HKD	0.00%		-2.31%	+2.29%

03-28	Aim Vaccine Submits Pre-Applications for Clinical Trials for Two Vaccines; Shares Up 3%	MT
03-28	Aim Vaccine's Loss Quadruples in 2023 as Revenue Slips 6%; Shares Up 3%	MT

AIM Vaccine Co., Ltd. Provides Earnings Guidance for the Year Ended December 31, 2023

March 03, 2024 at 11:50 pm

AIM Vaccine Co., Ltd. provided earnings guidance for the year ended December 31, 2023. The Group is expected to record an unaudited net loss ranging from RMB 1.81 billion to RMB 1.99 billion for the Year 2023, compared with a net loss of RMB 230 million for the year ended December 31, 2022.

Latest news about AIM Vaccine Co., Ltd.

Aim Vaccine Submits Pre-Applications for Clinical Trials for Two Vaccines; Shares Up 3%	03-28	MT
Aim Vaccine's Loss Quadruples in 2023 as Revenue Slips 6%; Shares Up 3%	03-28	MT
AIM Vaccine Co., Ltd. Submits the Pre- Application for Clinical Trials for Haemophilus Influenzae Type B Conjugate Vaccine	03-28	CI
AIM Vaccine Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	03-28	CI
AIM Vaccine Co., Ltd. Submits the Pre- Application for Clinical Trials for quadrivalent influenza virus vaccine (MDCK Cells)	03-27	CI
Aim Vaccine Submits Clinical Trial's Pre-Application for Rabies Vaccine	03-27	MT
AIM Vaccine Co., Ltd. Submits Pre-Application for Clinical Trials for Novel-Process Highly-Effective Human Diploid Rabies Vaccine	03-26	CI
AIM Vaccine Files Pre-Application for Marketing Registration of its Pneumonia Vaccine	03-05	MT
AIM Vaccine Boosts Development of Iterative Pneumonia Series Vaccines	03-04	MT
AIM Vaccine Expediting Development of Iterative Rabies Series Vaccines; Shares Drop 4%	03-04	MT
AIM Vaccine Advances Trial of Meningococcal Vaccine in China; Shares Fall 4%	03-04	MT
AIM Vaccine Expects Wider Loss in 2023; Shares Slide 4%	03-04	MT
AIM Vaccine Submits Pre-Application for Clinical Trials for Absorbed Tetanus Vaccine; Shares Fall 3%	03-04	MT
Aim Vaccine Co., Ltd. Initiation of Phase II Clinical Trial of Tetravalent Meningococcal Conjugate Vaccine	03-03	CI
AIM Vaccine Co., Ltd. Provides Earnings Guidance for the Year Ended December 31, 2023	03-03	CI
Aim Vaccine Co., Ltd. Announces Completion of the Layout of Iterative Rabies Vaccine Products and Fully Advancing the Research and Development of the Product Series	03-03	CI
AIM Vaccine Co., Ltd. Announces Completion of Application for Marketing of 13-Valent Pneumonia Conjugate Vaccine, Iterative Serum-Free Rabies Vaccine and 23-Valent Pneumonia Polysaccharide Vaccine	03-03	CI
Aim Vaccine Co., Ltd. Submits Pre-Application for Clinical Trials for Absorbed Tetanus Vaccine	03-03	CI
AIM Vaccine Co., Ltd. Submits the Pre- Application for Marketing Registration for Its 13-Valent Pneumonia Conjugate Vaccine	03-01	CI
AIM Vaccine Co., Ltd. Announces Executive Changes	02-29	CI
AIM Vaccine Co., Ltd. Announces Board Appointments	02-08	CI
Chairman Increases Stake in AIM Vaccine	01-10	MT
AIM Vaccine Chairman Boosts Stake in Firm	01-02	MT
Haoxiangni Health Food, Yankershop Food to Buy Minority Stakes in Local Snack Maker Lingshi Henmang	12-20	MT
AIM Vaccine Chairman Increases Shareholding; Shares Fall 3%	12-13	MT

Chart AIM Vaccine Co., Ltd.

Duration

Period

More charts

Company Profile

AIM Vaccine Co Ltd is a China-based company principally engaged in the research and development, manufacturing and sales of vaccine. The Company's products mainly include recombinant hepatitis B vaccine, human rabies vaccine, inactivated hepatitis A vaccine, mumps vaccine, inactivated hemorrhagic fever with renal syndrome vaccine and MPSV4. The Company's products are mainly used for the treatment of hepatitis B, hepatitis A, mumps, hemorrhagic fever with renal syndrome, rabies and meningococcal diseases. The Company's vaccine candidates include messenger RNA (mRNA) corona virus disease 2019 (COVID-19) vaccine, inactivated COVID-19 vaccine, broad-spectrum COVID-19 vaccine, PCV13, PPSV23 and MCV4. The Company principally conducts its businesses in the domestic market.

Sector

Pharmaceuticals

Calendar

28/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for AIM Vaccine Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

7.433 CNY

Average target price

48.74 CNY

Spread / Average Target

+555.76%

Consensus

Chiffre d''affaires - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
AIM VACCINE CO., LTD.	+2.29%	1.25B
CSL LIMITED	-2.32%	92.59B
SAMSUNG BIOLOGICS CO.,LTD.	+3.68%	41.43B
BIOGEN INC.	-10.90%	33.49B
BIOMARIN PHARMACEUTICAL INC.	-19.56%	14.62B
INCYTE CORPORATION	-9.06%	12.77B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-11.34%	11.58B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-43.53%	11.35B
SWEDISH ORPHAN BIOVITRUM AB	+3.75%	8.97B
INNOVENT BIOLOGICS, INC.	-6.32%	8.3B

Biopharmaceuticals